Evidence map›Paper›PMID 40893622›Full record

ArticleOphthalmology science

Retrospective OCT Analysis of Sphingosine-1-Phosphate Modulator Fingolimod in Multiple Sclerosis.

Wilson X Wang, Helen Rossmiller, Henok Getahun, Aditya Santoki, Dana C Perantie, Robert T Naismith, Rajendra S Apte

Abstract read
In one paragraph

Article in Ophthalmology science. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wilson X WangJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Helen RossmillerJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Henok GetahunJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Aditya SantokiJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.
Dana C PerantieDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri.
Robert T NaismithDepartment of Neurology, Washington University School of Medicine, St. Louis, Missouri.
Rajendra S ApteJohn F. Hardesty, MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Sphingosine-1-phosphate (S1P) plays a pivotal role in cells as a bioactive lipid mediator, with emerging evidence suggesting that it may play a role in retinal ganglion cell survival, axonal growth, retinal pigment epithelium (RPE) barrier function, and photoreceptor function. While previous studies have documented associated ophthalmic effects such as fingolimod-associated macular edema, the specific impact of S1P receptor modulators on inner and outer retinal layer thicknesses requires further elucidation. Design: Retrospective case series. Subjects: A total of 44 patients (86 eyes) with multiple sclerosis (MS) treated with fingolimod between 2011 and 2023 at the John L. Trotter Multiple Sclerosis Center at Washington University in St. Louis. Methods: Eligible participants were those with baseline and follow-up OCT images conducted at or prior to S1P initiation and at the most recent visit. The peripapillary retinal nerve fiber layer (pRNFL), ganglion cell layer (GCL), central subfield thickness (CST), macular volume (MV), RPE, and photoreceptor thickness were determined through OCT segmentation. Generalized estimating equations were constructed incorporating relevant covariates. Main Outcome Measures: Annualized rate of change of specified retinal layer thickness. Results: The mean age was 49.4 ± 10.8 years and time between baseline and follow-up OCTs ranged from 2 months to 6.4 years with a median of 1 year, interquartile range 0.42 to 2.33. The annualized rate of change of pRNFL and CST were 0.022 [-0.363, 0.406] μm/year, and -1.37 [-3.11, 0.38] μm/year, whereas GCL and MV showed significant thinning of -0.231 [-0.430, -0.032] μm/year and -0.024 [-0.047, -0.001] mm3/year, respectively. Retinal pigment epithelium and photoreceptor layer thickness remained largely stable over time at 0.070 [-0.140, 0.280] μm/year and 0.673 [-0.218, 1.561] μm/year, respectively. Conclusions: Patients with MS on S1P modulators exhibited significant GCL and MV thinning with outer retina layer thickness preservation, providing insight into the potential retinal effects of S1P modulation in the setting of MS-related neurodegeneration. Prospective studies with standardized imaging intervals and appropriate controls are needed to distinguish the specific retinal effect of S1P modulation from MS neurodegeneration and enable more precise OCT interpretation of the retina in monitoring MS disease progression. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Multiple sclerosisOCTPhotoreceptorsRNFLRPE

Identifiers

PMID40893622
PMCPMC12398846

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.